Metalytics, LLC

Biotech · Private

Software tools and modular assays for 13C metabolic flux analysis to measure cellular metabolic pathways

metalytics.bio →
Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Software and Services to Enable Metabolic Flux Analysis in Biotechnology Research$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2356Unnatural Products Inc.—$23M
2357CELLULAR LOGISTICS, INC.—$1.0M
2358NEW EQUILIBRIUM BIOSCIENCES, INC.—$10M
2359Metalytics, LLC——
2360OLIGOMERIX INC—$2.9M
2361Allinaire Therapeutics, LLC—$950K
2362ECM Therapeutics, Inc.—$919K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.